Cargando…
Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
This study aimed to analyze the survival rate and to examine the risk of death from prostate cancer when accounting for competing risk of death, in men aged ≥80 y treated with primary androgen deprivation therapy (ADT). Data of patients with prostate cancer who had received ADT were extracted from a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353900/ https://www.ncbi.nlm.nih.gov/pubmed/34014592 http://dx.doi.org/10.1111/cas.14974 |
_version_ | 1783736496443883520 |
---|---|
author | Blas, Leandro Onozawa, Mizuki Shiota, Masaki Hinotsu, Shiro Sakamoto, Shinichi Kitagawa, Yasuhide Kawai, Taketo Eto, Masatoshi Kume, Haruki Akaza, Hideyuki |
author_facet | Blas, Leandro Onozawa, Mizuki Shiota, Masaki Hinotsu, Shiro Sakamoto, Shinichi Kitagawa, Yasuhide Kawai, Taketo Eto, Masatoshi Kume, Haruki Akaza, Hideyuki |
author_sort | Blas, Leandro |
collection | PubMed |
description | This study aimed to analyze the survival rate and to examine the risk of death from prostate cancer when accounting for competing risk of death, in men aged ≥80 y treated with primary androgen deprivation therapy (ADT). Data of patients with prostate cancer who had received ADT were extracted from a nationwide community‐based database established by the Japan Study Group for Prostate Cancer. Prognostic variables, including progression‐free survival, cancer‐specific survival, overall survival, and death rates were compared between men stratified by prostate cancer risk. Overall, 4760 patients older than 80 y were included. The proportion of low‐, intermediate‐, high‐, or very high‐risk, regional, and metastatic prostate cancer among super‐elderly men was 9.5%, 14.6%, 48.8%, 9.0%, 3.2%, and 24.9%, respectively. Survival rates decreased with increasing risk stratification. The cumulative 5‐y death rate by prostate cancer for low‐, intermediate‐, high‐, or very high‐risk, regional, and metastatic prostate cancer, was 0.92% (95% confidence interval [CI]: 0.2%‐3.6%), 1.6% (95% CI: 0.8%‐3.4%), 5.75% (95% CI: 4.25%‐7.75%), 15.6% (95% CI: 11.6%‐23.3%), 20.7% (95% CI: 13.1%‐31.7%), and 36.9% (95% CI: 32.8%‐41.4%), respectively. Our findings support that there is no need for immediate ADT for low‐ and intermediate‐risk groups. Conversely, in high‐ or very high‐risk, regional, and metastatic prostate cancer, more efforts for curative therapy and intensive therapy are needed in selected patients. |
format | Online Article Text |
id | pubmed-8353900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83539002021-08-15 Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old Blas, Leandro Onozawa, Mizuki Shiota, Masaki Hinotsu, Shiro Sakamoto, Shinichi Kitagawa, Yasuhide Kawai, Taketo Eto, Masatoshi Kume, Haruki Akaza, Hideyuki Cancer Sci Original Articles This study aimed to analyze the survival rate and to examine the risk of death from prostate cancer when accounting for competing risk of death, in men aged ≥80 y treated with primary androgen deprivation therapy (ADT). Data of patients with prostate cancer who had received ADT were extracted from a nationwide community‐based database established by the Japan Study Group for Prostate Cancer. Prognostic variables, including progression‐free survival, cancer‐specific survival, overall survival, and death rates were compared between men stratified by prostate cancer risk. Overall, 4760 patients older than 80 y were included. The proportion of low‐, intermediate‐, high‐, or very high‐risk, regional, and metastatic prostate cancer among super‐elderly men was 9.5%, 14.6%, 48.8%, 9.0%, 3.2%, and 24.9%, respectively. Survival rates decreased with increasing risk stratification. The cumulative 5‐y death rate by prostate cancer for low‐, intermediate‐, high‐, or very high‐risk, regional, and metastatic prostate cancer, was 0.92% (95% confidence interval [CI]: 0.2%‐3.6%), 1.6% (95% CI: 0.8%‐3.4%), 5.75% (95% CI: 4.25%‐7.75%), 15.6% (95% CI: 11.6%‐23.3%), 20.7% (95% CI: 13.1%‐31.7%), and 36.9% (95% CI: 32.8%‐41.4%), respectively. Our findings support that there is no need for immediate ADT for low‐ and intermediate‐risk groups. Conversely, in high‐ or very high‐risk, regional, and metastatic prostate cancer, more efforts for curative therapy and intensive therapy are needed in selected patients. John Wiley and Sons Inc. 2021-06-29 2021-08 /pmc/articles/PMC8353900/ /pubmed/34014592 http://dx.doi.org/10.1111/cas.14974 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Blas, Leandro Onozawa, Mizuki Shiota, Masaki Hinotsu, Shiro Sakamoto, Shinichi Kitagawa, Yasuhide Kawai, Taketo Eto, Masatoshi Kume, Haruki Akaza, Hideyuki Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old |
title | Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old |
title_full | Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old |
title_fullStr | Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old |
title_full_unstemmed | Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old |
title_short | Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old |
title_sort | long‐term outcomes of androgen deprivation therapy in prostate cancer among japanese men over 80 years old |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353900/ https://www.ncbi.nlm.nih.gov/pubmed/34014592 http://dx.doi.org/10.1111/cas.14974 |
work_keys_str_mv | AT blasleandro longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT onozawamizuki longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT shiotamasaki longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT hinotsushiro longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT sakamotoshinichi longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT kitagawayasuhide longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT kawaitaketo longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT etomasatoshi longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT kumeharuki longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT akazahideyuki longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold AT longtermoutcomesofandrogendeprivationtherapyinprostatecanceramongjapanesemenover80yearsold |